Tumor Exosome Profiling Market Report 2026

Tumor Exosome Profiling Market Overview

• Tumor Exosome Profiling market size has reached to $1.13 billion in 2025 • Expected to grow to $2.49 billion in 2030 at a compound annual growth rate (CAGR) of 17.1% • Growth Driver: The Rise In Cancer Prevalence Driving The Growth Of The Market Due To Unhealthy Lifestyles • Market Trend: Innovative Blood Test Enables Early Cancer Detection And Personalized Therapy Monitoring • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Tumor Exosome Profiling Market?

Tumor exosome profiling refers to the analysis and characterization of exosomes small extracellular vesicles released by tumor cells, which carry molecular information such as proteins, ribonucleic acid, deoxyribonucleic acid (RNA, and DNA). This profiling helps in understanding tumor biology, identifying biomarkers, and developing diagnostic or therapeutic strategies for cancer management. The main product types of tumor exosome profiling include kits and reagents, instruments, software, and services. Kits and reagents are specialized materials used to isolate, detect, and analyze exosomes from biological samples, enabling accurate profiling for disease diagnostics and research. They are used with sample types such as blood, urine, saliva, and other sample types. The key applications of cancer diagnostics, prognostics, therapeutics, and research, while the end-use includes hospitals and clinics, research institutes, diagnostic laboratories, and other end-users.

What Is The Tumor Exosome Profiling Market Growth Forecast?

The tumor exosome profiling market size is expected to see rapid growth in the next few years. It will grow to $2.49 billion in 2030 at a compound annual growth rate (CAGR) of 17.1%. The growth in the forecast period can be attributed to integration of ai and bioinformatics in exosome profiling, development of personalized medicine solutions, expansion of diagnostic laboratories, adoption of high-throughput exosome analysis platforms, growth in cancer biomarker discovery. Major trends in the forecast period include liquid biopsy integration, high-throughput exosome analysis, automated sample preparation, multi-omics data profiling, personalized cancer therapeutics.

Global Tumor Exosome Profiling Market Segmentation

1) By Product Type: Kits And Reagents, Instruments, Software, Services 2) By Sample Type: Blood, Urine, Saliva, Other Sample Types 3) By Application: Cancer Diagnostics, Prognostics, Therapeutics, Research 4) By End-User: Hospitals And Clinics, Research Institutes, Diagnostic Laboratories, Other End-Users Subsegments: 1) By Kits And Reagents: Isolation Kits, Detection Kits, Quantification Kits, Labeling Reagents, Antibodies 2) By Instruments: Flow Cytometers, Nanoparticle Tracking Analyzers, Ultracentrifuges, Microfluidic Devices, Polymerase Chain Reaction Machines (PCR) Machines 3) By Software: Data Analysis Software, Visualization Software, Bioinformatics Platforms, Statistical Modeling Software, Exosome Tracking Software 4) By Services: Sample Preparation Services, Exosome Isolation Services, Molecular Profiling Services, Data Analysis Services, Custom Assay Development Services

What Is The Driver Of The Tumor Exosome Profiling Market?

The growing prevalence of cancer is expected to propel the growth of the tumor exosome profiling market going forward. Cancer refers to a group of diseases characterized by uncontrolled growth and division of abnormal cells, which can invade surrounding tissues and spread to other parts of the body. The growing prevalence of cancer is due to unhealthy lifestyles, including poor diet, lack of physical activity, smoking, and excessive alcohol consumption, which increase the risk of developing various types of cancer. Tumor exosome profiling helps in cancer by enabling early detection, monitoring tumor progression, and guiding personalized treatment strategies through the analysis of tumor-derived exosomes in body fluids. For instance, in February 2024, according to the World Health Organization, a Switzerland-based international organization specializing in global health policy and public health initiatives, over 35 million new cancer cases are predicted in 2050, a 77% increase from the estimated 20 million cases in 2022. Therefore, the growing prevalence of cancer is driving the rapid growth of the tumor exosome profiling industry.

Key Players In The Global Tumor Exosome Profiling Market

Major companies operating in the tumor exosome profiling market are Thermo Fisher Scientific Inc., Lonza Group Ltd., NanoFCM Inc., QIAGEN N.V., Bio-Techne Corporation, Miltenyi Biotec B.V. And Co. KG, Aethlon Medical Inc., Cusabio Technology LLC, Norgen Biotek Corp., Kimera Labs Inc, Diagenode Inc., Creative Biolabs Inc, Izon Science Ltd., System Biosciences LLC, Mercy Bioanalytics Inc, MtoZ Biolab, Capital Biosciences Inc., ExoCan Healthcare Technologies Private Limited, INOVIQ Ltd, Codiak BioSciences Inc.

Global Tumor Exosome Profiling Market Trends and Insights

Major companies operating in the tumor exosome profiling market are focusing on developing innovative solutions, such as liquid biopsy–based exosome assays, to enable early cancer detection and personalized therapy monitoring. A liquid biopsy–based exosome assay is a blood test that detects tiny vesicles called exosomes released by tumor cells, allowing doctors to identify and monitor cancer without invasive tissue biopsies. For instance, in June 2024, Mercy BioAnalytics Inc., a US-based biotechnology company, partnered with University College London (UCL), a UK-based university, to launch the Mercy Halo Ovarian Cancer Screening Test, a next generation extracellular vesicle liquid biopsy designed to identify ovarian cancer in asymptomatic, postmenopausal women by detecting multiple co localized cancer biomarkers on individual tumor derived vesicles using a low volume blood sample and quantitative polymerase chain reaction (qPCR) based read out, offering high sensitivity and specificity several years before clinical diagnosis.

What Are Latest Mergers And Acquisitions In The Tumor Exosome Profiling Market?

In September 2025, MDxHealth SA, a Belgium-based healthcare technology company, acquired Exosome Diagnostics, Inc. from Bio Techne Corporation for $15 million. With this acquisition, MDxHealth aims to expand its liquid based diagnostic capabilities and strengthen its leadership in prostate cancer diagnostics through the addition of ExoDx prostate cancer testing and related clinical laboratory assets. Exosome Diagnostics Inc. is a US-based healthcare technology company that specializes in providing comprehensive, proprietary tumor exosome profiling and liquid biopsy services.

Regional Insights

North America was the largest region in the tumor exosome profiling market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Tumor Exosome Profiling Market?

The tumor exosome profiling market consists of revenues earned by entities by providing services such as exosome isolation and purification, next-generation sequencing (ngs) services, custom exosome research services, exosome biomarker discovery and validation, and exosome-based liquid biopsy services. The market value includes the value of related goods sold by the service provider or included within the service offering. The tumor exosome profiling market also includes sales of exosome analysis and characterization instruments, bioinformatics software and analytics tools, affinity based isolation columns and spin column kits, high throughput microfluidic platforms, and exosome biomarker profiling libraries and reagents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data And Analysis Are Included In The Tumor Exosome Profiling Market Report 2026?

The tumor exosome profiling market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the tumor exosome profiling industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.